Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
Abstract
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is no reliable cure for the >240 million individuals that are chronically infected worldwide. Current treatments can only achieve viral suppression, and lifelong therapy is needed in the majority of infected persons. In the framework of the French National Agency for Research on AIDS and Viral Hepatitis ‘HBV Cure’ programme, a scientific workshop was held in Paris in June 2014 to define the state-of-the-art and unanswered questions regarding HBV pathobiology, and to develop a concerted strategy towards an HBV cure. This review summarises our current understanding of HBV host-interactions leading to viral persistence, as well as the roadblocks to be overcome to ultimately address unmet medical needs in the treatment of chronic HBV infection.Keywords
This publication has 166 references indexed in Scilit:
- Inactivation of Hepatitis B Virus Replication in Cultured Cells and In Vivo with Engineered Transcription Activator-Like Effector NucleasesMolecular Therapy, 2013
- Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus InfectionMolecular Therapy, 2013
- Towards an HIV cure: a global scientific strategyNature Reviews Immunology, 2012
- Design, Synthesis, and Biological Evaluation of Triazolo-pyrimidine Derivatives as Novel Inhibitors of Hepatitis B Virus Surface Antigen (HBsAg) SecretionJournal of Medicinal Chemistry, 2011
- Thiazolides as Novel Antiviral Agents. 1. Inhibition of Hepatitis B Virus ReplicationJournal of Medicinal Chemistry, 2011
- Liver antigen-presenting cellsJournal of Hepatology, 2011
- Zinc-finger Nucleases as a Novel Therapeutic Strategy for Targeting Hepatitis B Virus DNAsMolecular Therapy, 2010
- Defective hepatitis B virus DNA is not associated with disease status but is reduced by polymerase mutations associated with drug resistanceHepatology, 2008
- Hepatitis B virus infection initiates with a large surface protein–dependent binding to heparan sulfate proteoglycansHepatology, 2007
- Immunology of hepatitis B virus and hepatitis C virus infectionNature Reviews Immunology, 2005